News ID: 276686
Published: 0541 GMT November 13, 2020

Mustafa(pbuh) Prize laureate: Hero of COVID-19 vaccine development

Mustafa(pbuh) Prize laureate: Hero of COVID-19 vaccine development
Ugur Sahin

On Monday it was announced that the COVID-19 vaccine developed by the 2019 Mustafa(pbuh) Prize laureate has shown more than 90% efficacy.

The COVID-19 vaccine developed by BioNTech, cofounded by the 2019 Mustafa(pbuh) Prize laureate Ugur Sahin, and Pfizer, is found to be more than 90% effective based on initial trial results, said Pfizer’s CEO on Monday, November 9, MSTF Media reported. 

This is the first positive result in independent analysis of any COVID-19 vaccine in phase 3 trials.

It is estimated that the shot will be available for use by the end of this year, if drug authorities give their stamp of approval to this vaccine.

If emergency use authorization is granted to this mRNA vaccine, the companies estimate they can roll out up to 50 million doses by the end of 2020, which is enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

According to the data, out of the 43,000 trial participants, the independent evaluators were able to calculate the efficacy of the vaccine after two doses.

“To me, this is the best possible outcome,” said Ugur Sahin, cofounder and CEO of BioNTech.

The BioNTech vaccine results far exceed the FDA’s criteria for approving a COVID-19 vaccine. According to the World Health Organization (WHO), no vaccine is 100% effective.

Sahin said he expects the vaccine’s immune response to last for “at least one year,” adding that the vaccine-induced antibodies were shown to block about 20 different mutations of SARS-CoV-2.

“There’s a very low likelihood that a [mutation of] the virus can overcome the immune response,” he maintained.

The BioNTech and Pfizer vaccine uses messenger RNA (mRNA) technology, which is designed to trigger an immune response without using pathogens.

Ugur Sahin was awarded the 2019 Mustafa(pbuh) Prize in Life & Medical Science and Technology for his achievements in “Development and Clinical Testing of mRNA-based Cancer Vaccines that are Tailored to the Mutation Profile of a Cancer Patient.”

At the 2019 Mustafa(pbuh) Prize award ceremony, BioNTech’s senior vice president of RNA biochemistry and manufacturing, Andreas Kuhn, stated: “Rarely have I met anyone as smart as Mr. Sahin, he is always one step ahead of people. If you come up with a new idea, he has already reached that stage and anticipated it.”


  • Reuters
  • Financial Times
  • Deutsche Welle
Security Key:
Captcha refresh
Page Generated in 0/5179 sec